Lilly Creates Three-Way Deal To Share Risk In Alzheimer’s Drug Development
Executive Summary
In the face of the risky and costly drug development arena that is Alzheimer's disease, Lilly is receiving an infusion of more than $300 million from the investment community to fund an aggressive development plan for its two leading molecules for the brain disorder
You may also be interested in...
Alzheimer's Development Financing: Risky Therapies Call for Innovative Deals
Eli Lilly has hedged its bets on its two late-stage Alzheimer's disease candidates. In a deal with TPG-Axon and Quintiles' partnering group NovaQuest, Lilly sheds risk (and potentially reward) in this notoriously difficult therapeutic space. A model for private equity / pharma deals going forward?
Covance R&D Deal Meshes With Lilly’s “FIPNet” Model
Lilly has deepened its commitment to its fully integrated pharmaceutical network strategy, most recently adding a deal with the contract research organization Covance
Covance R&D Deal Meshes With Lilly’s “FIPNet” Model
Lilly has deepened its commitment to its fully integrated pharmaceutical network strategy, most recently adding a deal with the contract research organization Covance